BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38581379)

  • 1. Gammopathic dermopathy: characterization of cutaneous MGUS.
    Gordon ER; Chen C; Trager MH; Adeuyan O; Lapolla BA; Fahmy LM; Schreidah CM; Wetter DA; Geskin LJ
    Leuk Lymphoma; 2024 Apr; ():1-8. PubMed ID: 38581379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
    Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
    Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
    Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
    Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective analysis of multiple myeloma drug use in cutaneous toxicity of monoclonal gammopathy of undetermined significance.
    Gordon ER; Chen C; Adeuyan O; Lapolla BA; Trager MH; Fahmy LM; Schreidah CM; Wetter DA; Geskin LJ
    J Am Acad Dermatol; 2024 Mar; ():. PubMed ID: 38479611
    [No Abstract]   [Full Text] [Related]  

  • 6. The dilemma of treating pyoderma gangrenosum associated with monoclonal gammopathy of undetermined significance.
    Machan A; Azendour H; Frikh R; Hjira N; Boui M
    Dermatol Online J; 2020 May; 26(5):. PubMed ID: 32621712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients.
    Cao XX; Meng Q; Mao YY; Su W; Zhen JF; Shen KN; Zhang CL; Huang XF; Duan MH; Zhang W; Zhu TN; Cai HC; Chen M; Zhou DB; Li J
    Leuk Res; 2016 Jul; 46():85-8. PubMed ID: 27232065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression from Monoclonal gammopathy of undetermined significance of the immunoglobulin M class (IgM-MGUS) to Waldenstrom Macroglobulinemia is associated with an alteration in lipid metabolism.
    Jalali S; Shi J; Ahsan N; Wellik L; Serres M; Buko A; Paludo J; Kim H; Tang X; Yang ZZ; Novak A; Kyle R; Ansell S
    Redox Biol; 2021 May; 41():101927. PubMed ID: 33690107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal Gammopathy of Undetermined Significance.
    Gonsalves WI; Rajkumar SV
    Ann Intern Med; 2022 Dec; 175(12):ITC177-ITC192. PubMed ID: 36508741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurologic aspects of plasma cell disorders.
    Sobol U; Stiff P
    Handb Clin Neurol; 2014; 120():1083-99. PubMed ID: 24365373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.
    Kleinstern G; Larson DR; Allmer C; Norman AD; Muntifering G; Sinnwell J; Visram A; Rajkumar V; Dispenzieri A; Kyle RA; Slager SL; Kumar S; Vachon CM
    Blood Cancer J; 2022 Apr; 12(4):67. PubMed ID: 35440099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.
    Tedeschi A; Conticello C; Rizzi R; Benevolo G; Laurenti L; Petrucci MT; Zaja F; Varettoni M
    Hematol Oncol; 2019 Apr; 37(2):117-128. PubMed ID: 30192023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the understanding of IgM monoclonal gammopathy of undetermined significance.
    Paludo J; Ansell SM
    F1000Res; 2017; 6():2142. PubMed ID: 29399323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Kyle RA; Rajkumar SV
    Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.
    Go RS; Gundrum JD; Neuner JM
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):177-186.e4. PubMed ID: 25445471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory and clinical characterization of monoclonal gammopathy in Taiwanese.
    Lee LN; Jan IS; Tien HF; Lin JS; Lo SC; Cheng WC
    J Formos Med Assoc; 2002 Feb; 101(2):91-7. PubMed ID: 12099210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunostaining of skin biopsy adds no diagnostic value in MGUS-associated peripheral neuropathy.
    Al-Zuhairy A; Schrøder HD; Plesner T; Abildgaard N; Sindrup SH
    J Neurol Sci; 2015 Feb; 349(1-2):60-4. PubMed ID: 25582978
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.